Which has the lower trailing P/E, BIO or HSIC?

HSIC has the lower trailing P/E: BIO trades at 46.26 and HSIC at 25.51. P/E is one valuation measure and does not by itself establish which business is cheaper.

Which has grown faster, BIO or HSIC?

Over the past five years, HSIC grew revenue faster — BIO at a 0.29% CAGR versus HSIC at 2.71%.

Is BIO or HSIC more profitable?

BIO runs the higher net margin — BIO at 8.59% versus HSIC at 2.96%.

How have BIO and HSIC total returns compared?

Over the past 10 years, BIO delivered 8.88% and HSIC delivered 3.56% annualized total return. Past performance doesn't predict future results.

Bio-Rad Laboratories, Inc. (BIO) vs Henry Schein, Inc. (HSIC)

A side-by-side comparison of Bio-Rad Laboratories, Inc. and Henry Schein, Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of September 13, 2026. Differences are shown without an overall score or investment verdict.

BIO

Bio-Rad Laboratories, Inc.

$10.27B

$381.62HealthcareDelayed quote: Sep 22, 2026, 3:35 PM EDT

HSIC

Henry Schein, Inc.

$9.97B

$87.51HealthcareDelayed quote: Sep 22, 2026, 3:35 PM EDT

Total return — BIO vs HSIC

growth of $100 · dividends reinvested · last 10y

BIO +131.2% (+8.7%/yr)HSIC +37.3% (+3.2%/yr)BIO compounded faster over this window

BIO HSIC

BIO vs HSIC: by the numbers

•BIO is the larger company ($10.27B vs $9.97B market cap).
•HSIC trades at the lower trailing earnings multiple (25.51 vs 46.26 P/E), one valuation lens rather than an overall verdict.
•BIO converts more revenue to profit (8.59% vs 2.96% net margin).
•HSIC grew revenue faster over the past five years (2.71% vs 0.29% CAGR).

Metrics side by side

Valuation

Metric	BIO	HSIC
P/E ratio	46.26	25.51
Forward P/E	39.59	16.25
P/S ratio	3.97	0.73
P/B ratio	1.43	3.16
EV / EBITDA	28.65	12.53
FCF yield	3.44%	5.41%

Profitability

Metric	BIO	HSIC
Gross margin	51.90%	30.31%
Operating margin	9.08%	5.69%
Net margin	8.59%	2.96%
ROE	3.10%	12.77%
ROIC	1.54%	6.53%

Growth (annualized)

Metric	BIO	HSIC
Revenue CAGR (5Y)	0.29%	2.71%
EPS CAGR (5Y)	-26.27%	3.14%
FCF CAGR (5Y)	-9.65%	0.82%
Total return CAGR (5Y)	-14.74%	2.85%

Frequently asked

Which has the lower trailing P/E, BIO or HSIC?: HSIC has the lower trailing P/E: BIO trades at 46.26 and HSIC at 25.51. P/E is one valuation measure and does not by itself establish which business is cheaper.
Which has grown faster, BIO or HSIC?: Over the past five years, HSIC grew revenue faster — BIO at a 0.29% CAGR versus HSIC at 2.71%.
Is BIO or HSIC more profitable?: BIO runs the higher net margin — BIO at 8.59% versus HSIC at 2.96%.
How have BIO and HSIC total returns compared?: Over the past 10 years, BIO delivered 8.88% and HSIC delivered 3.56% annualized total return. Past performance doesn't predict future results.

Go deeper

Full BIO analysis Full HSIC analysis Interactive comparison tool

Dig into the metrics

Bio-Rad Laboratories P/E ratio Henry Schein P/E ratio Bio-Rad Laboratories ROE Henry Schein ROE Bio-Rad Laboratories operating margin Henry Schein operating margin Bio-Rad Laboratories revenue growth Henry Schein revenue growth Bio-Rad Laboratories free cash flow Henry Schein free cash flow

Bio-Rad Laboratories & Henry Schein appear in these rankings

Highest FCF Yield Stocks

Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified September 13, 2026.